<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALCIFEDIOL</span><br/>(kal-si-fe-dye'ole)<br/><span class="topboxtradename">Calderol<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">vitamin d analog</span><br/><b>Prototype: </b>Calcitriol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mcg, 50 mcg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Vitamin D analog and major transport form of cholecalciferol (D<sub>3</sub>) Vitamin D analog is fat soluble. Because it is activated in the body and has regulatory effects, it is considered a hormone.
         Primary action leads to regulation of serum calcium, which is affected also by the activity of other vitamin D analogs (e.g.,
         ergocalciferol), parathyroid hormone, and calcitonin. Pharmacologic effects of calcifediol are related to its intrinsic vitamin
         D activity as well as to the properties of active metabolites (e.g., calcitriol), which result from renal metabolism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Helps to maintain serum calcium in patients undergoing chronic renal dialysis and effective in renal osteodystrophy and promotes
         healing in hepatic osteomalacia.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of metabolic bone disease and hypocalcemia associated with chronic renal failure in patients undergoing renal dialysis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Osteopenia caused by prolonged glucocorticoid therapy and osteomalacia secondary to hepatic disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to vitamin D, vitamin D toxicity, hypercalcemia. Safe use of doses in excess of RDA during pregnancy (category
         C), lactation, and children not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients receiving digitalis glycosides.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metabolic Bone Disease in Patients With Chronic Renal Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initially 300350 mcg/wk administered on a daily or alternate day schedule, may increase at 4-wk intervals if necessary;
               patients with normal calcium may only need 20 mcg q.o.d. (usual range 50100 mcg/d <i>or</i> 100200 mcg q.o.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Since calcitriol is a metabolite of vitamin D<sub>3</sub>, all sources of vitamin D are usually withheld during therapy or at least must be considered when calculating dosage.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Muscle or bone pain, idiosyncratic reaction (headache, nausea, vomiting, diarrhea, fever). <span class="typehead">GI:</span> Anorexia, nausea, vomiting, dry mouth, thirst, constipation, diarrhea, abdominal cramps, metallic taste. <span class="typehead">Metabolic:</span> Vitamin D intoxication, hypercalcemia, polyuria, hypercalciuria, hyperphosphatemia. <span class="typehead">CNS:</span> Lethargy, headache, weakness, vertigo. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">thiazide diuretics</span> may cause hypercalcemia; may precipitate digitalis arrhythmias with <b>digoxin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from small intestines. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Duration:</span> 1520 d. <span class="typehead">Distribution:</span> Stored chiefly in liver and fat deposits. <span class="typehead">Metabolism:</span> Activated in kidneys. <span class="typehead">Elimination:</span> Excreted primarily in bile and feces. <span class="typehead">Half-Life:</span> 1222 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine baseline and periodic values for serum calcium, phosphorus, magnesium, and alkaline phosphatase. Monitor
            serum calcium whenever dosage adjustments are made. Measure urinary calcium and phosphorus levels q24h.
         </li>
<li>Effectiveness of therapy depends on an adequate daily intake of calcium. Since dietary calcium and phosphate are difficult
            to control, the physician may prescribe a calcium supplement as needed.
         </li>
<li>Monitor for manifestations of hypercalcemia (see Appendix F). If hypercalcemia occurs, discontinue calcifediol until serum
            calcium returns to normal (910.6 mg/dL).
         </li>
<li>Report a fall in serum alkaline phosphatase as this usually signals the onset of hypercalcemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take this drug if experiencing S&amp;S of hypercalcemia (see Appendix F), and report immediately to physician.</li>
<li>Consult physician before taking an OTC medication. Calcium, phosphate, or magnesium-containing laxatives and antacids, mineral
            oil, and vitamin D preparations may increase adverse effects of calcifediol and therefore should be avoided.
         </li>
<li>
            							Note: Patients undergoing dialysis may require aluminum carbonate or hydroxide gels to bind intestinal phosphate and thus lower
            serum phosphate levels.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>